Altogether, it appears that the precise impact of GDF15 in dyslipidaemia, especially in the context of atherosclerosis, remains to be elucidated in order to ascertain whether this molecule can represent a useful pharmacological target to combat the occurrence of dyslipidaemia in MetS. Here, GDF15 is linked to metabolic syndrome.